Prognostic Value of Tumor Markers in Pancreatic Cancer
Author Information
Author(s): J. Lundin, P.J. Roberts, P. Kuusela, C. Haglund
Primary Institution: University of Helsinki
Hypothesis
Can preoperative serum levels of CA 19-9 and CEA predict survival in pancreatic cancer patients?
Conclusion
Preoperative CA 19-9 levels have prognostic value in stage II-III pancreatic cancer patients.
Supporting Evidence
- Patients with CA 19-9 below 370 U/ml had better survival rates.
- Significant survival differences were found in stage II-III patients based on CA 19-9 levels.
- CEA levels above 15 ng/ml were associated with shorter survival in stage IV patients.
Takeaway
Doctors can use blood tests to check certain markers to help predict how long someone with pancreatic cancer might live.
Methodology
Serum samples were collected from patients and analyzed for CA 19-9 and CEA levels, comparing survival based on these levels.
Potential Biases
Potential bias due to exclusion of patients who died shortly after surgery.
Limitations
The study did not account for all factors influencing prognosis, and some patients were excluded from analysis.
Participant Demographics
Patients with histologically or cytologically verified exocrine pancreatic carcinoma.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website